---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-045527"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2026-10-02T20:30:32+00:00"
generated_at: "2026-10-12T14:38:48.416639+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cingulate extends CMO Matthew Brams' trial period to Dec 31, 2026 at $400,000 base salary

## Summary
- Amendment No. 2 to the employment agreement of Matthew N. Brams, EVP and Chief Medical Officer, extends his Trial Period from September 30, 2026 to December 31, 2026.
- Brams' annual base salary is set at $400,000 for 100% full-time effort, effective January 1, 2026 through December 31, 2026.
- At the end of the Trial Period, CEO Shane J. Schaffer has sole discretion to keep Brams full-time or return him to a part-time role at a lower base salary.
- All other provisions of the January 1, 2026 employment agreement remain unchanged.

## SEC filing metadata
- accession: 0001493152-26-045527
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2026-10-02T20:30:32+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315226045527/0001493152-26-045527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315226045527/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-045527
- JSON: https://secwatch.observer/filing/0001493152-26-045527.json
- Plain text: https://secwatch.observer/filing/0001493152-26-045527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.